OTC Markets EXMKT - Delayed Quote USD

Onward Medical N.V. (ONWRF)

5.19

0.00

(0.00%)

At close: November 18 at 3:00:00 PM EST

ONWARD Medical Announces First Commercial Sales of ARC-EX System

UW Medicine and Next Steps Chicago both purchased systems in late December 2024 ARC-EX is the first and only FDA approved technology indicated to improve hand strength and sensation in people with spinal cord injury ARC-EX was named a 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence

GlobeNewswire 3 days ago

ONWRF
0.00%
Onward wins FDA approval for ARC-EX system in spinal cord injury patients

Shares in the company were up 7% at market open following the first approval for a non-invasive spinal cord stimulator for spinal cord injury (SCI) patients.

Medical Device Network 22 days ago

ONWD.BR
ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)ARC-EX System is the first and only FDA approved technology shown to improve hand strength and sensation after chronic spinal cord injuryARC-EX System is an FDA Breakthrough Device and 2024 TIME Magazine Best InventionEINDHOVEN, the Netherlands, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 5:45pm December 19, 2024 -- ONWARD Medical N.V. (Euronext: ONWD), the medical technolo

GlobeNewswire 23 days ago

ONWRF
0.00%
ONWARD Medical Ranks in Top 15 Percent Globally for Corporate Sustainability

EcoVadis silver medal recognizes Company's environmental and social impact Demonstrates ongoing commitment to integrating sustainable business practices EINDHOVEN, the Netherlands, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces it has been awarded a silver medal by EcoVadis, the world

GlobeNewswire last month

ONWRF
0.00%
ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights

Raised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company’s top investor Signed exclusive license with CEA to develop and commercialize WIMAGINE Brain-Computer Interface (BCI) as part of the Company’s investigational ARC-BCI System Rob ten Hoedt, former Medtronic President and Executive Committee member, joined Board of Directors as incoming Chairman EINDHOVEN, the Netherlands, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical

GlobeNewswire last month

ONWRF
0.00%
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke

Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke Funding also supports technology development of ARC-BCI System and ARC-IM Lead Approximately 15 million people worldwide experience a stroke each year EINDHOVEN, the Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal

GlobeNewswire last month

ONWRF
0.00%
ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date Highlights

Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEAEINDHOVEN, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q3 2024 business

GlobeNewswire last month

ONWRF
0.00%
ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EX System has been named one of TIME's Best Inventions of 2024. "We are grateful for TIME’s recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord i

GlobeNewswire 2 months ago

ONWRF
0.00%
ONWARD® Medical Publishes Closing of Bookbuild Offering

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 28, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today the closing of its previously announced

GlobeNewswire 2 months ago

ONWRF
0.00%
Onward raises $54m to continue neuromodulation trials

Germany-based Ottobock SE & Co. KGaA will hold an approximate 10% stake in Onward’s share capital, following the investment.

Clinical Trials Arena 2 months ago

ONWD.BR
ONWARD® Medical Publishes Prospectus for Listing of New Shares

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today that it has published a prospectus for

GlobeNewswire 2 months ago

ONWRF
0.00%
ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global leader in the fields of prosthetics, orthotics and exoskeleton technology, acquires c.10% of ONWARD Medical N.V.’s share capital and initiates strategic relationship Cash runway extended to two years or more Capital increase was upsized to EUR 50M on the basis of strong demand from high-quality long-only and sector specialist investors EINDHOVE

GlobeNewswire 2 months ago

ONWRF
0.00%
ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global player in the fields of prosthetics, orthotics and

GlobeNewswire 2 months ago

ONWRF
0.00%
ONWARD® Medical Announces Changes to Board of Directors, Including Addition of Medtech Leader Rob ten Hoedt as Incoming Chairman

Jan Ohrstrom Jan Ohrstrom to retire after 8 years of service Rob ten Hoedt Medtech leader Rob ten Hoedt will become Chairman of the Board of Directors Rahma Samow Incoming Board Director Ten Hoedt is a former Medtronic President and Executive Committee Member; also a former Chairman of MedTech Europe Commercial and digital health expert Rahma Samow will also join as Director Current Board Chairman Jan Ohrstrom and Director Fred Colen to retire from the Board at year-end after 8 years of service

GlobeNewswire 2 months ago

ONWRF
0.00%
ONWARD Medical licenses WIMAGINE BCI for spinal cord injury treatment

WIMAGINE BCI is a key component of CEA’s ARC-BCI system, aiming to restore movement in paralysis patients.

Medical Device Network 2 months ago

ONWD.BR
ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec’s WIMAGINE® Brain-Computer Interface (BCI) Technology

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company secures exclusive rights to incorporate the WIMAGINE BCI into its ARC-BCI™ System WIMAGINE BCI has 7-year human safety data Deal provides opportunity for ONWARD to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysis EINDHOVEN, the Netherlands, Oct. 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD

GlobeNewswire 2 months ago

ONWRF
0.00%
ONWARD® Medical Announces Third Implant of Brain-Computer Interface (BCI) System to Restore Movement after Spinal Cord Injury

Company continues pioneering research on BCI-enabled system to restore mobility after spinal cord injuryEINDHOVEN, The Netherlands, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces another successful implant of its investigational ARC-BCI™ System to restore lower limb mobility after SCI. The

GlobeNewswire 3 months ago

ONWRF
0.00%
ONWARD® Medical Reports Half Year 2024 Results and Provides a Business Update

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Up-LIFT Study results published in Nature Medicine De Novo application submitted to FDA to obtain clearance to market the investigational ARC-EX® System in the United States Up to EUR 52.5M in growth financing obtained from US-based Runway Growth Capital Several additional milestones achieved with the investigational ARC-BCI™ System, leveraging brain-computer inter

GlobeNewswire 4 months ago

ONWRF
0.00%
Onward wins grant from Christopher & Dana Reeve Foundation to advance BCI study

The $1.1m grant will fund the enrolment of an additional four participants to be implanted with Onward’s ARC-BCI system.

Medical Device Network 4 months ago

ONWD.BR
ONWARD® Medical and Partners Awarded Christopher & Dana Reeve Foundation Grant to Further Study Brain-Computer Interface System

Grant will enable ONWARD Medical, CEA-Clinatec and .NeuroRestore to evaluate the use of the ONWARD ARC-BCI™ System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI)EINDHOVEN, the Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a grant

GlobeNewswire 4 months ago

ONWRF
0.00%

Performance Overview

Return	ONWRF	BEL 20
YTD	-13.50%	+0.19%
1-Year	+36.94%	+13.76%
3-Year	-18.27%	-1.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Onward Medical N.V. (ONWRF)

ONWARD Medical Announces First Commercial Sales of ARC-EX System

Onward wins FDA approval for ARC-EX system in spinal cord injury patients

ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury

ONWARD Medical Ranks in Top 15 Percent Globally for Corporate Sustainability

ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights

ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke

ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date Highlights

ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

ONWARD® Medical Publishes Closing of Bookbuild Offering

Onward raises $54m to continue neuromodulation trials

ONWARD® Medical Publishes Prospectus for Listing of New Shares

ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA

ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA

ONWARD® Medical Announces Changes to Board of Directors, Including Addition of Medtech Leader Rob ten Hoedt as Incoming Chairman

ONWARD Medical licenses WIMAGINE BCI for spinal cord injury treatment

ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec’s WIMAGINE® Brain-Computer Interface (BCI) Technology

ONWARD® Medical Announces Third Implant of Brain-Computer Interface (BCI) System to Restore Movement after Spinal Cord Injury

ONWARD® Medical Reports Half Year 2024 Results and Provides a Business Update

Onward wins grant from Christopher & Dana Reeve Foundation to advance BCI study

ONWARD® Medical and Partners Awarded Christopher & Dana Reeve Foundation Grant to Further Study Brain-Computer Interface System

Performance Overview